Evidence map›Paper›PMID 38290769›Full record

ArticleJournal for immunotherapy of cancer2024

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.

Kosaku Mimura, Takashi Ogata, Phuong H D Nguyen, Souvick Roy, Hassen Kared, Yate-Ching Yuan, Michael Fehlings, Yuya Yoshimoto, Daisaku Yoshida, Shotaro Nakajima and 17 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03453164 (Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03453164 phase1 / phase2completednot on this map

Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy (CIRCUIT).

TypeinterventionalSponsorFukushima Medical UniversityRan2018 to 2021Enrolled41ConditionsGastric CancerArmsRadiotherapy, Nivolumab
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 3 countries.

Kosaku MimuraDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0003-2565-154X
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Phuong H D NguyenImmunoScape, Singapore.
Souvick RoyDepartment of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, California, USA.
Hassen KaredImmunoScape, Singapore.
Yate-Ching YuanDivision of Translational Bioinformatics, Center for Informatics, City of Hope National Medical Center, Duarte, California, USA.
Michael FehlingsImmunoScape, Singapore.
Yuya YoshimotoDepartment of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Daisaku YoshidaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Shotaro NakajimaDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hisashi SatoDepartment of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Nozomu MachidaDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Takanobu YamadaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yohei WatanabeDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Tomoaki TamakiDepartment of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hirohito FujikawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yasuhiro InokuchiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Suguru HayaseDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hiroyuki HanayamaDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Zenichiro SazeDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hiroyuki KatohDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Fumiaki TakahashiDepartment of Information Science, Iwate Medical University, Yahaba, Japan.
Takashi OshimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Ajay GoelDepartment of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, California, USA.
Alessandra NardinImmunoScape, Singapore.
Yoshiyuki SuzukiDepartment of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Koji KonoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan kojikono@fmu.ac.jp.
Fukushima Medical University · JPKanagawa Prefectural Hospital Organization · JPSingapore Immunology Network · SGCity of Hope · USCity Of Hope National Medical Center · USIwate Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor-associated antigen (TAA)-specific CD8(+) T cells are essential for nivolumab therapy, and irradiation has been reported to have the potential to generate and activate TAA-specific CD8(+) T cells. However, mechanistic insights of T-cell response during combinatorial immunotherapy using radiotherapy and nivolumab are still largely unknown.

methodsTwenty patients included in this study were registered in the CIRCUIT trial (ClinicalTrials.gov, NCT03453164). All patients had multiple distant metastases and were intolerance or had progressed after primary and secondary chemotherapy without any immune checkpoint inhibitor. In the CIRCUIT trial, eligible patients were treated with a total of 22.5 Gy/5 fractions/5 days of radiotherapy to the largest or symptomatic lesion prior to receiving nivolumab every 2 weeks. In these 20 patients, T-cell responses during the combinatorial immunotherapy were monitored longitudinally by high-dimensional flow cytometry-based, multiplexed major histocompatibility complex multimer analysis using a total of 46 TAAs and 10 virus epitopes, repertoire analysis of T-cell receptor β-chain (TCRβ), together with circulating tumor DNA analysis to evaluate tumor mutational burden (TMB).

resultsAlthough most TAA-specific CD8(+) T cells could be tracked longitudinally, several TAA-specific CD8(+) T cells were detected de novo after irradiation, but viral-specific CD8(+) T cells did not show obvious changes during treatment, indicating potential irradiation-driven antigen spreading. Irradiation was associated with phenotypical changes of TAA-specific CD8(+) T cells towards higher expression of killer cell lectin-like receptor subfamily G, member 1, human leukocyte antigen D-related antigen, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain, CD160, and CD45RO together with lower expression of CD27 and CD127. Of importance, TAA-specific CD8(+) T cells in non-progressors frequently showed a phenotype of CD45RO(+)CD27(+)CD127(+) central memory T cells compared with those in progressors. TCRβ clonality (inverted Pielou's evenness) increased and TCRβ diversity (Pielou's evenness and Diversity Evenness score) decreased during treatment in progressors (p=0.029, p=0.029, p=0.012, respectively). TMB score was significantly lower in non-progressors after irradiation (p=0.023).

conclusionOligo-fractionated irradiation induces an immune-modulating effect with potential antigen spreading and the combination of radiotherapy and nivolumab may be effective in a subset of patients with gastric cancer.

Indexed as

NivolumabStomach NeoplasmsCD8-Positive T-LymphocytesHumansImmunityImmunotherapyLeukocyte Common AntigensLeukocyte Common AntigensNivolumabcombination therapygastric cancerimmune checkpoint inhibitorimmune modulatoryradiotherapy/radioimmunotherapy

Identifiers

PMID38290769
PMCPMC10828861
OpenAlexW4391345021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.